Showing results (771-780 of 881) with videos related to
Sort By:
Pageof 89
The New England Journal of Medicine|April 1, 2011
Boceprevir for untreated chronic HCV genotype 1 infectionFred Poordad, Jonathan McCone, Bruce R Bacon, et al.The Journal of Infectious Diseases|August 2, 2013
Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individualsGregory M Lucas, Yuezhou Jing, Mark Sulkowski, et al.Hepatology (Baltimore, Md.)|May 24, 2012
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirinIra M Jacobson, Patrick Marcellin, Stefan Zeuzem, et al.Hepatology Communications|February 7, 2018
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatmentEdward J Gane, Sophie Metivier, Ronald Nahass, et al.Alimentary Pharmacology & Therapeutics|January 29, 2015
Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevirR K Sterling, A Kuo, V K Rustgi, et al.Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1Stefan Zeuzem, Mark S Sulkowski, Eric J Lawitz, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 StudyDavid Wyles, Norbert Bräu, Shyam Kottilil, et al.AIDS (London, England)|July 17, 2007
Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infectionGregory J Dore, Francesca J Torriani, Maribel Rodriguez-Torres, et al.Hepatology (Baltimore, Md.)|May 13, 2017
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimenEdward J Gane, Mitchell L Shiffman, Kyle Etzkorn, et al.Journal of the International AIDS Society|November 14, 2014
Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimensJoseph J Eron, Jay Lalezari, Jihad Slim, et al.Pageof 89